MARKET

BCLI

BCLI

Brainstorm Cell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.920
-0.010
-0.25%
Closed 16:00 12/09 EST
OPEN
3.920
PREV CLOSE
3.930
HIGH
3.961
LOW
3.910
VOLUME
43.90K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
2.920
MARKET CAP
88.62M
P/E (TTM)
-4.0041
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BCLI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BCLI News

  • UPDATE 2-Mexico's Televisa wins injunction on part of Disney-Fox deal; merger unaffected
  • Reuters.4d ago
  • UPDATE 1-Televisa wins injunction over Disney purchase of Fox assets in Mexico
  • Reuters.4d ago
  • Hedge fund titan Steve Cohen in talks to increase his stake in Mets
  • CNBC.com.5d ago
  • Mayor Pete is Hollywood's top pick now that Kamala Harris is out of the presidential race
  • CNBC.com.5d ago

More

Industry

Biotechnology & Medical Research
+0.51%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Name
Price
%Change

About BCLI

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
More

Webull offers Brainstorm Cell Therapeutics Inc (BCLI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.